Depression - Pipeline Review, H2 2018

Depression - Pipeline Review, H2 2018


  • Products Id :- GMDHC10764IDB
  • |
  • Pages: 504
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Depression-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression-Pipeline Review, H2 2018, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 33, 30, 76, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 7

Depression-Overview 8

Depression-Therapeutics Development 9

Depression-Therapeutics Assessment 32

Depression-Companies Involved in Therapeutics Development 47

Depression-Drug Profiles 86

Depression-Dormant Projects 449

Depression-Discontinued Products 466

Depression-Product Development Milestones 471

Appendix 484

List of Figures

Number of Products under Development for Depression, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Depression, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Depression-Pipeline by Acadia Pharmaceuticals Inc, H2 2018

Depression-Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018

Depression-Pipeline by Adamed Sp z oo, H2 2018

Depression-Pipeline by Addex Therapeutics Ltd, H2 2018

Depression-Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Depression-Pipeline by Albany Molecular Research Inc, H2 2018

Depression-Pipeline by Alkermes Plc, H2 2018

Depression-Pipeline by Allergan Plc, H2 2018

Depression-Pipeline by Amorsa Therapeutics Inc, H2 2018

Depression-Pipeline by Anavex Life Sciences Corp, H2 2018

Depression-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Depression-Pipeline by Axsome Therapeutics Inc, H2 2018

Depression-Pipeline by Azevan Pharmaceuticals Inc, H2 2018

Depression-Pipeline by BioCrea GmbH, H2 2018

Depression-Pipeline by Bionomics Ltd, H2 2018

Depression-Pipeline by BioXcel Therapeutics Inc, H2 2018

Depression-Pipeline by Blackthorn Therapeutics Inc, H2 2018

Depression-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Depression-Pipeline by Bristol-Myers Squibb Co, H2 2018

Depression-Pipeline by Calico LLC, H2 2018

Depression-Pipeline by Celgene Corp, H2 2018

Depression-Pipeline by Cellix Bio Pvt Ltd, H2 2018

Depression-Pipeline by Celon Pharma SA, H2 2018

Depression-Pipeline by Cerecor Inc, H2 2018

Depression-Pipeline by Clera Inc, H2 2018

Depression-Pipeline by Delpor Inc, H2 2018

Depression-Pipeline by DURECT Corp, H2 2018

Depression-Pipeline by Eisai Co Ltd, H2 2018

Depression-Pipeline by Eli Lilly and Co, H2 2018

Depression-Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018

Depression-Pipeline by FPRT Bio Inc, H2 2018

Depression-Pipeline by GlaxoSmithKline Plc, H2 2018

Depression-Pipeline by GliaCure Inc, H2 2018

Depression-Pipeline by H. Lundbeck AS, H2 2018

Depression-Pipeline by Heptares Therapeutics Ltd, H2 2018

Depression-Pipeline by Impel NeuroPharma Inc, H2 2018

Depression-Pipeline by Intas Pharmaceuticals Ltd, H2 2018

Depression-Pipeline by IntelGenx Corp, H2 2018

Depression-Pipeline by Intra-Cellular Therapies Inc, H2 2018

Depression-Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2018

Depression-Pipeline by Johnson & Johnson, H2 2018

Depression-Pipeline by Karuna Pharmaceuticals Inc, H2 2018

Depression-Pipeline by KemPharm Inc, H2 2018

Depression-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Depression-Pipeline by Lead Discovery Center GmbH, H2 2018

Depression-Pipeline by Les Laboratoires Servier SAS, H2 2018

Depression-Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Depression-Pipeline by Luye Pharma Group Ltd, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acadia Pharmaceuticals Inc

Ache Laboratorios Farmaceuticos SA

Adamed Sp z oo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Albany Molecular Research Inc

Alkermes Plc

Allergan Plc

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

Bionomics Ltd

BioXcel Therapeutics Inc

Blackthorn Therapeutics Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calico LLC

Celgene Corp

Cellix Bio Pvt Ltd

Celon Pharma SA

Cerecor Inc

Clera Inc

Delpor Inc

DURECT Corp

Eisai Co Ltd

Eli Lilly and Co

Fabre-Kramer Pharmaceuticals Inc

FPRT Bio Inc

GlaxoSmithKline Plc

GliaCure Inc

H. Lundbeck AS

Heptares Therapeutics Ltd

Impel NeuroPharma Inc

Intas Pharmaceuticals Ltd

IntelGenx Corp

Intra-Cellular Therapies Inc

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

Karuna Pharmaceuticals Inc

KemPharm Inc

Kissei Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Luye Pharma Group Ltd

Mapi Pharma Ltd

Mapreg SAS

MedinCell SA

Medlab Clinical Ltd

Meta-IQ ApS

Mitsubishi Tanabe Pharma Corp

Navitor Pharmaceuticals Inc

Neuralstem Inc

Neurocrine Biosciences Inc

NeuroNascent Inc

Nippon Chemiphar Co Ltd

Novartis AG

Omeros Corp

Otsuka Holdings Co Ltd

Pfizer Inc

Pherin Pharmaceuticals Inc

Protagenic Therapeutics Inc

Relmada Therapeutics Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Shenox Pharmaceuticals LLC

SK Biopharmaceuticals Co Ltd

Sound Pharmaceuticals Inc

Sumitomo Chemical Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Syntropharma Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Trevena Inc

VistaGen Therapeutics Inc

Zysis Ltd

Depression Therapeutic Products under Development, Key Players in Depression Therapeutics, Depression Pipeline Overview, Depression Pipeline, Depression Pipeline Assessment

select a license
Single User License
USD 2000 INR 142480
Site License
USD 4000 INR 284960
Corporate User License
USD 6000 INR 427440

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com